Skip to main content
Journal cover image

VEGF inhibitors in cancer therapy.

Publication ,  Journal Article
Cardones, AR; Banez, LL
Published in: Curr Pharm Des
2006

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is thought to play a critical role in tumor growth and metastasis. Consequently, anti-VEGF therapies are being actively investigated as potential anti-cancer treatments, either as alternatives or adjuncts to conventional chemo or radiation therapy. Among the techniques used to block the VEGF pathway are: 1) neutralizing monoclonal antibodies against VEGF or its receptor, 2) small molecule tyrosine kinase inhibitors of VEGF receptors, 3) soluble VEGF receptors which act as decoy receptors for VEGF, and 4) ribozymes which specifically target VEGF mRNA. Recent evidence from phase III clinical trials led to the approval of bevacizumab, an anti-VEGF monoclonal antibody, by the FDA as first line therapy in metastatic colorectal carcinoma in combination with other chemotherapeutic agents. However, may challenges still remain, and the role of anti-VEGF therapy in the treatment of other solid tumors remains to be elucidated. The aim of this article is to review the progress of clinical investigations involving VEGF inhibitors in the treatment of different types of solid tumors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Pharm Des

DOI

ISSN

1381-6128

Publication Date

2006

Volume

12

Issue

3

Start / End Page

387 / 394

Location

United Arab Emirates

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Receptors, Vascular Endothelial Growth Factor
  • Neoplasms
  • Medicinal & Biomolecular Chemistry
  • Immunotherapy
  • Humans
  • Antineoplastic Agents
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cardones, A. R., & Banez, L. L. (2006). VEGF inhibitors in cancer therapy. Curr Pharm Des, 12(3), 387–394. https://doi.org/10.2174/138161206775201910
Cardones, Adela R., and Lionel L. Banez. “VEGF inhibitors in cancer therapy.Curr Pharm Des 12, no. 3 (2006): 387–94. https://doi.org/10.2174/138161206775201910.
Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des. 2006;12(3):387–94.
Cardones, Adela R., and Lionel L. Banez. “VEGF inhibitors in cancer therapy.Curr Pharm Des, vol. 12, no. 3, 2006, pp. 387–94. Pubmed, doi:10.2174/138161206775201910.
Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des. 2006;12(3):387–394.
Journal cover image

Published In

Curr Pharm Des

DOI

ISSN

1381-6128

Publication Date

2006

Volume

12

Issue

3

Start / End Page

387 / 394

Location

United Arab Emirates

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Receptors, Vascular Endothelial Growth Factor
  • Neoplasms
  • Medicinal & Biomolecular Chemistry
  • Immunotherapy
  • Humans
  • Antineoplastic Agents
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences